COMMUNIQUÉS West-GlobeNewswire

Dr. Austin Harris Revolutionizes Mental Health and Pain Management with Personalized, Integrative Ketamine Therapy
18/03/2026
SHERMAN OAKS, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Dr. Austin Harris , a board-certified cardiothoracic anesthesiologist and the founder of NeuroRelief Ketamine & Infusion Therapy, is redefining the treatment [...]
ProKidney Reports Full Year 2025 Financial Results and Business Highlights
18/03/2026
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the [...]
MATTER 360 Diverts 7.7 Million Pounds of Medical Surplus from Landfills in 2025
18/03/2026
Minneapolis, MN, March 18, 2026 (GLOBE NEWSWIRE) -- Minnesota-based global NGO MATTER announced today that its MATTER 360 initiative successfully diverted more than 7.7 million pounds of medical surplus from landfills [...]
Totus Medicines Presents Phase 1a Clinical Data for TOS-358, a Covalent PI3Ka Inhibitor, at ESMO TAT 2026
18/03/2026
Oral presentation of Ph 1a clinical data highlights potential best-in-class drug profile in heavily pretreated patients with PI3K a -mutant metastatic breast cancer and other solid tumors Overall, TOS-358 demonstrated [...]
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
18/03/2026
WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the [...]
Azalea Therapeutics Highlights Nature Publication Demonstrating In Vivo Site-Specific TRAC-CAR T Cell Engineering
18/03/2026
Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platform Peer-reviewed publication demonstrates stable, cell-specific transgene expression through in vivo site- [...]
Centre for Neuro Skills Expands Employer Partnerships Strategy, Appoints Jay Varma as Director
18/03/2026
CNS strengthens its engagement with employers, health plans and benefits advisors to expand access to specialized neuro center of excellence BAKERSFIELD, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Centre for Neuro [...]
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
18/03/2026
First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe. Strategic Account: This new lab’s [...]
OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms
18/03/2026
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today [...]
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
18/03/2026
Approval marks a historic milestone for Americans living with ssAR who are at high risk for surgery and previously had no dedicated transcatheter treatment option IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- [...]
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
18/03/2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study
18/03/2026
Investigator-sponsored trial backed by Glaucoma UK and HSC R&D Division targets rapidly growing patient population; first enrollment expected Q2 2026 BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo [...]
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
18/03/2026
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF [...]
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
18/03/2026
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, [...]
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome
18/03/2026
DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable [...]
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
18/03/2026
• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collaborators’ expertise [...]
Amphista Therapeutics appoints Louise Modis Ph.D. as CEO and Patrick Kelly M.D. as CMO and provides a business update as the Company prepares to file IND application for AMX-883
18/03/2026
Strengthening the clinical leadership as the Company progresses to the clinic with its BRD9 Targeted Glue™, AMX-883, in acute myeloid leukemia Amphista continues to advance its SMARCA and TEAD programs to key inflection [...]
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
18/03/2026
FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut Extract Company has signed an option agreement with [...]
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
18/03/2026
DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the [...]

Pages